Related references
Note: Only part of the references are listed.Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
M. Chalabi et al.
ANNALS OF ONCOLOGY (2020)
Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer
Xiayao Diao
THORACIC CANCER (2020)
Proton Pump Inhibitors Reduce Pancreatic Adenocarcinoma Progression by Selectively Targeting H+, K+-ATPases in Pancreatic Cancer and Stellate Cells
Marco Tozzi et al.
CANCERS (2020)
Development of a novel aortic dissection mouse model and evaluation of drug efficacy using in-vivo assays and database analyses
Yuki Izawa-Ishizawa et al.
JOURNAL OF HYPERTENSION (2019)
Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
Chris Plummer et al.
BRITISH JOURNAL OF CANCER (2019)
Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database
Yoshito Zamami et al.
FRONTIERS IN PHARMACOLOGY (2019)
Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database
Naoto Okada et al.
CANCER MEDICINE (2019)
Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
Ka Shing Cheung et al.
GUT (2018)
We have had a gutful: The need for deprescribing proton pump inhibitors
M. Naunton et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2018)
Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events
Rhian M. Touyz et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2018)
Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism
Minjian Zhao et al.
ONCOLOGY REPORTS (2017)
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
David Miles et al.
EUROPEAN JOURNAL OF CANCER (2017)
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden
Nele Brusselaers et al.
BMJ OPEN (2017)
Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism
Takuya Nagashima et al.
SCIENTIFIC REPORTS (2016)
Association between bevacizumabrelated hypertension and response to treatment in patients with metastatic colorectal cancer
Isabel Jose Dionisio de Sousa et al.
ESMO OPEN (2016)
Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?
Bradley R. Corr et al.
GYNECOLOGIC ONCOLOGY REPORTS (2016)
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Fariba Ahmadizar et al.
PLOS ONE (2015)
Fucoidan Reduces Secretion and Expression of Vascular Endothelial Growth Factor in the Retinal Pigment Epithelium and Reduces Angiogenesis In Vitro
Michaela Dithmer et al.
PLOS ONE (2014)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients
Esther Tahover et al.
MEDICAL ONCOLOGY (2013)
Systems Pharmacology of Adverse Event Mitigation by Drug Combinations
Shan Zhao et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Inappropriate prescribing of proton pump inhibitors in hospitalized patients
Mark Reid et al.
JOURNAL OF HOSPITAL MEDICINE (2012)
Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
P. Oesterlund et al.
BRITISH JOURNAL OF CANCER (2011)
Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
Alfonso De Stefano et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Hypertension as a Predictive Factor of Effect of Bevacizumab in Treatment of Colorectal Cancer
Yuya Horinouchi et al.
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2011)
Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
Carie S. Facemire et al.
HYPERTENSION (2009)
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study
Howard S. Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
R Edgar et al.
NUCLEIC ACIDS RESEARCH (2002)
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
EP van Puijenbroek et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2002)
KEGG: Kyoto Encyclopedia of Genes and Genomes
M Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
